UCB have published a series of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer
Filed under: kinase | Tagged: kinase, PI3K, UCB | Comments Off
UCB publish series for PI3K inhibitors
Posted on July 28, 2008 by crimsoncanary
Nexavar approved for hepatocellular carcinoma in China
Posted on July 28, 2008 by crimsoncanary
Bayer and Onyx have announced that Nexavar has been approved for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer in China
Filed under: kinase | Tagged: Approval, bayer, kinase, multikinase, Nexavar, onyx, regulatory, sorafenib | Comments Off
Astex publish series of CDK2 inhibitors
Posted on July 28, 2008 by crimsoncanary
Exelixis MET/RET/VEGFR2 inhibitor XL184 achieves proof of concept in cancer
Posted on July 28, 2008 by crimsoncanary
Exelixis have announced that its MET/RET/VEGFR2 inhibitor XL184 has achieved proof of concept in hematologic cancers. The company has submitted data to its partner GSK who has 90 days to review the data and decide whether to exercise its option to select the compound for further development and commercialization.
Filed under: Uncategorized | Tagged: Exelixis, GSK, kinase, Met, phase iii, RET, VEGFR2, XL-184, XL184 | Comments Off
